Myanmar
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2012 53 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 25 (12–44) 48 (23–84)
Mortality (HIV+TB only) 4.6 (3.8–5.3) 8.8 (7.3–10)
Prevalence  (includes HIV+TB) 260 (200–320) 489 (377–616)
Incidence  (includes HIV+TB) 200 (170–230) 377 (322–435)
Incidence (HIV+TB only) 19 (16–21) 35 (30–41)
Case detection, all forms (%) 71 (62–83)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 42 909 (31) Relapse 4 558 (40)
Smear-negative 73 042 (53) Treatment after failure 1 671 (14)
Smear-unknown / not done 0 (0) Treatment after default 521 (5)
Extrapulmonary 20 661 (15) Other 4 787 (41)
Other 0 (0)      
Total new 136 612   Total retreatment 11 537  
           
Other (history unknown) 0        
Total new and relapse 141 170   Total cases notified 148 149  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.9    
Age < 15 338    
Laboratories 2012
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Is second-line drug susceptibility testing available? Yes, in and outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 90  
Retreatment 72  
TB/HIV 2012 Number (%)
TB patients with known HIV status 19 219 (13)
HIV-positive TB patients 5 161 (27)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 4 270 (83)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 4.2 (3.1–5.6) 10 (6.9–14)
MDR-TB cases among notified pulmonary
TB cases
4 900 (3 600–6 500) 1 200 (790–1 600)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     778
Patients started on MDR-TB treatment     442
Financing TB control 2013
National TB programme budget (US$ millions) 36
% Funded domestically 2%
% Funded internationally 39%
% Unfunded 60%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-17 Data: www.who.int/tb/data